ERBB2 and ductal breast carcinoma in situ: Our original DCIS vaccine trial targeting HER-2 showed that only around 5% of patients with estrogen receptor (ER)-expressing tumors experienced pCR to neoadjuvant vaccination, while about 40% of ERneg patients had pCRs [4].